Vaporox Joins Catalyst HTI

Posted by Mike Biselli on 8.21.2019

DENVER –  Vaporox, Inc., a medical device company dedicated to healing chronic skin wounds, is proud to announce that they have joined the Catalyst HTI ecosystem in Denver, Colorado. “We chose to join Catalyst because of the concentration of medical expertise and the ability to meet and share ideas with both startups and mature companies in the industry,” said Alan Sage, CEO of Vaporox. “It is so great to be surrounded by so many other driven people developing products to improve patient lives.”

Vaporox has developed a patented and FDA-cleared technology called Vaporous Hyperoxia Therapy (VHT™), which accelerates the healing of 9 different types of wounds. For Example, chronic diabetic foot ulcers (DFUs), which are both painful and debilitating, generate annual healthcare costs around $15 billion/year in the U.S. alone. DFUs are the leading cause of non-traumatic lower extremity amputations in the US.

In a completed clinical trial, VHT achieved almost 3 times the healing of standard wound care. “Deploying VHT nationally could cut healthcare costs by $10 billion/year and prevent almost 100,000 amputations annually,” said Alan Sage.

VHT works by encapsulating the limb in a chamber where an ultrasonic vapor of water and ionic silver is introduced to fight infection and bring moisture to the wound. This is followed by applying pure oxygen at slight positive pressure. The ionic silver anti-microbial suppresses “bio-burden,” while the aqueous mist and the oxygen reproduce the conditions that would exist with healthy blood circulation, thus enabling the body to heal itself.

“At Catalyst, I see many medical device companies making a big impact on the lives of patients with debilitating conditions like diabetes,” said Catalyst HTI’s president, Mike Biselli. “Having the Vaporox team on campus is a shining example of the amazing technologies being built in Colorado and the companies that call our building home!”

Vaporox is actively raising a $1.53M Series Seed round.

About Vaporox
Vaporox was formed to commercialize Vaporous Hyperoxia Therapy (VHT™), a patented and FDA-510K-cleared technology that represents a breakthrough in treating 9 different types of skin wounds, including diabetic foot ulcers (DFUs). This innovative technology has been shown to generate up to three times the healing of the standard of care for DFUs. For more information, visit

About Catalyst HTI
Located in Denver, Colorado’s River North District (RiNo), Catalyst HTI is a 180,000 square-foot industry integrator designed to bring health-tech start-ups and established health care entities together under one roof. The building covers an entire block, located on the west side of Brighton Boulevard between 35th and 36th Streets. Catalyst HTI’s goal is to bring together private enterprise (startups to Fortune 100), government, academic and non-profit organizations with healthcare providers and payers to accelerate innovation and drive real, lasting change. For more information visit